Venus Remedies Limited — Oxaliplatin Exporter Profile
Indian Pharmaceutical Exporter · #8 for Oxaliplatin · $1.5M export value · DGFT Verified
Venus Remedies Limited is the #8 Indian exporter of Oxaliplatin with $1.5M in export value and 132 verified shipments. Venus Remedies Limited holds a 3.2% market share in Oxaliplatin exports across 14 countries. The company exports 29 pharmaceutical products worth $86.4M across 6 therapeutic categories.
Venus Remedies Limited — Oxaliplatin Export Profile: Buyers & Destinations
Where Does Venus Remedies Limited Export Oxaliplatin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| THAILAND | $925.2K | 51 | 62.9% |
| MOROCCO | $119.0K | 13 | 8.1% |
| PAKISTAN | $99.8K | 16 | 6.8% |
| ZIMBABWE | $97.0K | 18 | 6.6% |
| KENYA | $61.4K | 9 | 4.2% |
| IRAQ | $50.1K | 2 | 3.4% |
| TANZANIA | $45.9K | 8 | 3.1% |
| PHILIPPINES | $36.6K | 5 | 2.5% |
| VENEZUELA | $15.1K | 4 | 1.0% |
| GAUTEMALA | $7.2K | 1 | 0.5% |
Venus Remedies Limited exports Oxaliplatin to 14 countries. The largest destination is THAILAND accounting for 62.9% of Venus Remedies Limited's Oxaliplatin shipments, followed by MOROCCO (8.1%) and PAKISTAN (6.8%). These destinations reflect Venus Remedies Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Oxaliplatin from Venus Remedies Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| C M C L | THAILAND | $606.1K | 27 |
| C M C L COSMA MEDICAL CO LIMITED | THAILAND | $120.2K | 7 |
| COSMA MEDICAL CO.LTD. | THAILAND | $73.8K | 6 |
| P P | MOROCCO | $69.9K | 6 |
| COSMA MEDICAL CO.,LTD. | THAILAND | $58.3K | 7 |
| CMCL | THAILAND | $54.5K | 2 |
| KIMADIA | IRAQ | $50.1K | 2 |
| NATPHARM CO | ZIMBABWE | $50.0K | 1 |
| H.P.P.L | PAKISTAN | $32.7K | 3 |
| H L | KENYA | $31.9K | 6 |
Venus Remedies Limited supplies Oxaliplatin to 44 buyers globally. The largest buyer is C M C L (THAILAND), followed by C M C L COSMA MEDICAL CO LIMITED (THAILAND) and COSMA MEDICAL CO.LTD. (THAILAND). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Oxaliplatin Export Value and How Much Does Venus Remedies Limited Contribute?
India exported $32.6M worth of Oxaliplatin through 3,081 shipments from 249 suppliers to 123 countries, serving 693 buyers globally. Venus Remedies Limited contributes $1.5M to this total, accounting for 3.2% of India's Oxaliplatin exports. Venus Remedies Limited ships Oxaliplatin to 14 countries through 44 buyers.
What Is the Average Shipment Value for Venus Remedies Limited's Oxaliplatin Exports?
Venus Remedies Limited's average Oxaliplatin shipment value is $11.3K per consignment, based on 132 shipments totaling $1.5M. The largest destination is THAILAND (62.9% of Venus Remedies Limited's Oxaliplatin exports).
How Does Venus Remedies Limited Compare to Other Indian Oxaliplatin Exporters?
Venus Remedies Limited ranks #8 among 249 Indian Oxaliplatin exporters with a 3.2% market share. The top 3 exporters are FRESENIUS KABI ONCOLOGY LIMITED ($16.6M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($3.6M), ACCURE LABS PRIVATE LIMITED ($2.6M). Venus Remedies Limited processed 132 shipments to 14 destination countries.
What Oxaliplatin Formulations Does Venus Remedies Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| OXALIPLATIN INJECTION ( 100MG/50 ML ) E | $50.0K | 1 |
| OXOL 100MG/50ML (OXALIPLATIN INJECTION U | $50.0K | 1 |
| OXALIPLATIN INJECTION 100MG/20ML.OXOL 5MG/ ML INJ.EACH ML CONTAINS: OXALIPLATIN5 MG WATER FOR INJ. QS | $50.0K | 1 |
| OXOL 5MG/ML INJ.OXALIPLATIN INJECTION 1 | $48.1K | 1 |
| OXOL 5 MG/ ML INJECTION OXALIPLATIN INJECTION 100MG/20ML | $47.9K | 1 |
| OXALIPLATIN INJECTION 100MG/20ML OXOL 5MG/ ML INJ. BN.X5BOX044A, X5BOX054A MFG.DT. 02/2025, EXP. DT. 01/2027 | $41.4K | 1 |
| OXALIPLATIN INJ.100 MG/20 ML.OXOL 5 MG/ML INJ).BNO.X4DOX074AMD.04/24ED.03/26BNO.X4DOX044AMD.05/24ED.04/26 | $35.9K | 1 |
| OXALIPLATIN INJECTION 100MG/20ML OXOL 5MG/ ML INJ. BATCH NO. X4AOX054B, MFG. DT. 01/2024, EXP. DT. 12/2025 | $35.5K | 1 |
| OXALIPLATIN INJECTION 100MG/50ML OXOL 100 MG BATCH NO.X4BOX022C , MFG. DT. 02/2024, EXP. DT. 01/2026 | $35.5K | 1 |
| OXALIPLATIN INJ.100MG/20ML OXOL 5 MG/MLINJ.BATCH NO. X4COX214B, X4COX224A MFG.DT. 03/2024, EXP. DT. 02/2026 | $35.5K | 1 |
Venus Remedies Limited exports 128 distinct Oxaliplatin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is OXALIPLATIN INJECTION ( 100MG/50 ML ) E with 1 shipments worth $50.0K.
How Does Venus Remedies Limited Compare to Nearest Oxaliplatin Exporters?
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | JODAS EXPOIM PRIVATE LIMITED | $1.6M | 32 | 1 | $50.0K |
| 7 | NAPROD LIFE SCIENCES PRIVATE LIMITED | $1.5M | 51 | 9 | $29.4K |
| 8 | VENUS REMEDIES LIMITED ★ | $1.5M | 132 | 14 | $11.3K |
| 5 | GLAND PHARMA LIMITED | $1.0M | 20 | 1 | $50.0K |
| 9 | ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED | $850.0K | 17 | 10 | $50.0K |
Venus Remedies Limited ranks #8 among 249 Indian Oxaliplatin exporters. Average shipment value of $11.3K compared to the market average of $130.9K. The closest competitors by value are JODAS EXPOIM PRIVATE LIMITED and NAPROD LIFE SCIENCES PRIVATE LIMITED.
Which Indian Ports Ship Oxaliplatin Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 535 | 17.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 453 | 14.7% |
| DELHI AIR | 436 | 14.2% |
| SAHAR AIR | 410 | 13.3% |
| CHAWAPAYAL ICD (INCPR6) | 110 | 3.6% |
| Bombay Air | 108 | 3.5% |
| NHAVA SHEVA SEA (INNSA1) | 97 | 3.1% |
| CHAWAPAYAL ICD | 95 | 3.1% |
What Other Advanced Oncology Products Does Venus Remedies Limited Export?
Venus Remedies Limited also exports these advanced oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Venus Remedies Limited's Oxaliplatin Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Venus Remedies. The ongoing Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing transit times and costs for exports to Europe and the Americas. Such disruptions necessitate strategic adjustments in logistics and supply chain management to maintain timely deliveries and cost-effectiveness.
Conversely, the U.S.-China trade tensions have opened avenues for Indian pharmaceutical companies to strengthen their presence in the U.S. market. India now supplies 40% of the U.S.'s generic drug needs, reflecting a growing reliance on Indian manufacturers. (ibef.org) Venus Remedies' recent QIDP designation from the U.S. FDA for VRP-034 positions the company favorably to leverage this opportunity, potentially enhancing its market share in the U.S.
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains critical. Venus Remedies' renewal of the EU-GMP certification indicates their proactive approach to meeting stringent EU regulations, thereby ensuring continued access to European markets. (business-standard.com)
Venus Remedies Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for pharmaceutical exporters. Venus Remedies has demonstrated a consistent commitment to quality, as evidenced by multiple GMP certifications. In addition to the EU-GMP renewal, the company secured GMP certification from Moldova's Ministry of Health in January 2025, covering their antibiotic-carbapenem manufacturing facility. (apnnews.com) Furthermore, the renewal of Ukrainian GMP certification in May 2025 for their Baddi facility underscores their adherence to global quality standards. (apnnews.com)
These certifications not only facilitate market access but also enhance the company's reputation as a reliable supplier of high-quality pharmaceuticals. In an industry where regulatory compliance is closely scrutinized, Venus Remedies' proactive measures position them favorably among global competitors.
About Venus Remedies Limited
Venus Remedies Limited exports 29 products worth $86.4M. Beyond Oxaliplatin, top products include Meropenem, Imipenem, Enoxaparin, Ceftriaxone, Paclitaxel. View the complete Venus Remedies Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Oxaliplatin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Oxaliplatin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Venus Remedies Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 133 individual customs records matching Venus Remedies Limited exporting Oxaliplatin, covering 128 formulations to 14 countries via 44 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 123+ countries, 693+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Oxaliplatin Export Data from Venus Remedies Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Venus Remedies Limited's Oxaliplatin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Venus Remedies Limited
Full Company Profile →
29 products · $86.4M total trade · 6 categories
Oxaliplatin Stats
Company Overview
Top Products by Venus Remedies Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Venus Remedies Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Oxaliplatin. For current shipment-level data, contact TransData Nexus.